Search PubMed⌕ Search

Biomedical subjects

D Bowen

Publications and source records attributed to D Bowen.

At least 91 records · Page 5Linked to original sources

Oral acyclovir to suppress recurring herpes simplex virus infections in immunodeficient patients.

Thirty-two episodes of herpes simplex virus infection in four immunodeficient patients with frequent recurrences were successfully treated with oral acyclovir, one capsule five times a day for 5 days. In 23 of these episodes, the treatments were extended for 1 to 6 months using two to five capsules a day with the aim of suppressing expected recurrences. In these patients, who routinely had more than one recurrence per month before treatment, there were only six outbreaks during more than 60 patient-months of suppressive therapy. Infection always recurred after treatments were completed, but the time to recurrence was shorter after treatments with two acyclovir capsules per day than after treatments with five capsules per day (p less than 0.001).

Acyclovir↗

Some considerations in the experimental approach to distinguishing between membrane transport and intracellular disposition of antineoplastic agents, with specific reference to fluorodeoxyuridine, actinomycin D, and methotrexate.

Analysis of the interaction between an anticancer agent and the intact cell can provide important clues to cytotoxic determinants and mechanisms of drug selectivity and resistance. This can be very useful in optimally evaluating single and multidrug regimens in test systems, designing new agents, and evaluating drug metabolism and binding to cellular target sites. This cellular pharmacokinetic approach requires very meticulous attention to experimental design, especially the time dimension chosen for study, and an appropriate framework for data analysis. This paper reviews cellular pharmacokinetic principles and experimental approaches that can be applied in "uptake studies" with cytotoxic agents, focusing, as examples, on studies from this laboratory with fluorodeoxyuridine, actinomycin D, and methotrexate.

Animals↗

The interaction between fluoropyrimidines and methotrexate, and [4C]-formate incorporation into nucleic acids and protein.

Changes are reported in [14C]-formate incorporation into nucleic acids and protein of Ehrlich ascites tumor cells during exposure to methotrexate (MTX) and fluoropyrimidines. The rate of [14C]-formate incorporation into RNA, DNA, and protein in the presence of only MTX was inhibited by 82%, 91%, and 75% respectively, when compared with control rates. However, in the presence of 5-fluorodeoxyuridine (FdUrd) plus MTX, formate incorporation into RNA, DNA, and protein was inhibited by 67%, 85%, and 66%. Incubation of cells in vitro with [3H]-dihydrofolate (DHF) results in its rapid conversion to [3H]-tetrahydrofolate (THF). The THF/DHF ratio from the soluble fraction of cells that were incubated with [3H]-DHF was 43% greater in the presence of FdUrd and MTX than in the presence of MTX alone. As the rate of [3H]-dUrd incorporation into DNA was reduced by 88% and 99% by pretreating cells with 0.1 muM and 1 muM FdUrd, respectively, the inhibitory effect of MTX on [14C]-formate incorporation into (a) RNA was decreased by 63% and 46%; (b) DNA was decreased by 74% and 61%; and (c) protein was decreased by 63% and 32%. These data suggest that fluoropyrimidines can antagonize the effects of MTX on purines or nucleic acid synthesis and protein synthesis by preventing the consumption of THF for dTMP synthesis.

Animals↗

A basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro.

The inhibitory effect of methotrexate on [3H]deoxyuridine incorporation into DNA is reduced as the basal rate of this reaction is inhibited by pretreatment of Ehrlich ascites tumor cells with fluoropyrimidines. This observation is a basis for fluoropyrimidine-methotrexate antagonism in anticancer regimens and supports the concept that the sensitivity of thymidylate synthesis in tumor cells to methotrexate is related, in part, to the basal rate of thymidylate synthesis from deoxyuridylate.

Animals↗

The relationship among transport, intracellular binding, and inhibition of RNA synthesis by actinomycin D in Ehrlich ascites tumor cells in vitro.

Uptake of actinomycin D (AD) was characterized in Ehrlich ascites tumor cells in vitro. The time course of uptake consists of an initial component that represents a unidirectional flux of AD into the cells, following which the net uptake rate falls to achieve a velocity that is constant over a 45-min interval of observation. The velocity of influx exceeds that of the late uptake phase by a factor of 2. Influx is 1st order over an AD concentration range of 0.02 to 14 muM. Influx is highly temperature sensitive (Q10 = 4.5); this is related only in part to the high temperature dependence (Q10 =2) of the oil-adqueous partition coefficient for this agent. Within 4 min after exposure of cells to AD, a component of intracellular AD appears which exceeds the concentration of extracellular AD and rapidly leaves the cells (t 1/2 congruent to 3 min) when the cells are resuspended into an AD-free medium. The level of this component of intracellular drug is unaffected by metabolic poisons, and the apparent chemical gradient is attributed to loose binding. While transport of AD does not appear to be energy-dependent, the data do not clafity whether translocation across the cell membrane is diffusional or carrier mediated. In addition to a loosely bound intracellular component, analysis of the unidirectional net efflux of AD indicates at least 3 other exit components; one with a t 1/2 of 35 min, a very tightly bound component, and another representing drug that is free within the intracellular water, The bulk of AD taken up is tightly bound to intracellular constituents, and the rate of accumulation of this cellular component accounts almost entirely for the net rate of uptake of AD during the late uptake phase. Because influx exceeds the rate of tight binding within the cell by a factor of only 2, it is unlikely that osmotically active AD achieves thermodynamic equilibrium across the cell membrane over the interval of these experiments. Rather, prior to saturation of binding sites within the cell, the level of free AD achieved is probably below the extracellular concentration. Since the rate of binding should be influenced by the level of free intracellular AD, factors that increase influx and bring the intracellular AD level closer to equilibrium should also increase the rate of intracellular binding. Tween 80 augments both influx and AD binding within the cell, an effect that may be related to augmented transport alone, but an additional stimulatory effect on the binding process is also possible. Association of AD with only a small number of the very-high-affinty intracellular binding sites, in the absence of free or loosely bound AD, results in approximately 35% inhibition of [2-14C]uridine incorporation into RNA within 50 sec after exposure of cells to 1 muM AD. Within 10 min. 75% inhibition is achieved indicating that association of AD with only a small fraction of the total high-affinity sites is sufficient to suppress RNA synthesis.

Animals↗

Patterning.

Explore the source record for details and available documents.

Brain Damage, Chronic↗

Making change happen.

Explore the source record for details and available documents.

Community-Institutional Relations↗